Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Checkmate Pharmaceuticals is raising $15,999,999.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Barry Labinger played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Checkmate Pharmaceuticals

Checkmate Pharmaceuticals is a clinical stage biopharmaceutical company focused upon activation of innate immunity to treat cancer. At Checkmate Pharmaceuticals, we believe that every person living with cancer should have the best odds for better outcomes. Our clinical programs are focused on enabling more people with cancer to benefit from the promise of novel immunotherapies. Based on decades of experience pioneering Toll-like receptor (TLR) therapies, we are demonstrating the power and the potential of activating the immune system to improve cancer care and patient outcomes. Checkmate Pharmaceuticals is a team of scientists, physicians and life sciences entrepreneurs discovering and developing new approaches to fighting cancer. Together, we’re striving to checkmate cancer.

To learn more about Checkmate Pharmaceuticals, visit http://checkmatepharma.com/

Contact:
Barry Labinger, Chief Executive Officer
978-503-2124
blabinger@checkmatepharma.com
https://www.linkedin.com/in/barry-labinger-783b8011/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved